Company Overview of Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds include brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, as well as to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections. Its preclinical testing product includes CMX669 for the treatment of BK virus and CMV. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of ...
2505 Meridian Parkway
Durham, NC 27713
Founded in 2000
Key Executives for Chimerix, Inc.
Chief Executive Officer, President, Chief Medical Officer and Director
Total Annual Compensation: $419.3K
Chief Commercial Officer
Total Annual Compensation: $333.6K
Chief Medical Officer
Total Annual Compensation: $128.5K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2014.
Chimerix, Inc. Key Developments
Chimerix, Inc. Provides Earnings Guidance for the Full Year 2015
Aug 6 15
Chimerix, Inc. provided earnings guidance for the full year 2015. For the full year 2015, the company expects loss from operations was $25 million for the second quarter of 2015 compared to a loss from operations of $11.6 million for the same period in 2014. The variance was due primarily to the increased research and development and general and administrative expenses.
Chimerix, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 6 15
Chimerix, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported a net loss of $24.8 million, or $0.59 per basic and diluted share, for the second quarter of 2015. During the same period in 2014, the company recorded a net loss of $11.7 million, or $0.39 per basic and diluted share. Revenues for the second quarter of 2015 increased to $4.1 million compared to $0.9 million for the same period in 2014, due to an increase in the second quarter of 2015 in reimbursable expenses associated with the company's ongoing development contract with Biomedical Advanced Research and Development Authority (BARDA), and the recognition of deferred revenue related to the company's collaboration and licensing agreement with ContraVir Pharmaceuticals. Loss from operations was $25.0 million for the second quarter of 2015, compared to a loss from operations of $11.6 million for the same period in 2014. The variance was primarily due to the increased research and development, and general and administrative expenses.
For the six months, the company reported net loss of $47.080 million or $1.13 per diluted share on total revenue of $5.381 million compared to net loss of $22.134 million or $0.78 per diluted share on total revenue of $1.699 million reported in the same period last year. Loss from operations was $42.279 million against $21.780 million reported last year.
Chimerix, Inc. Completes Targeted Enrollment for Brincidofovir Phase 3 Advise Trial for Adenovirus Infection
Aug 3 15
Chimerix, Inc. announced completion of enrollment of the targeted 200 patients in the Phase 3 AdVise trial evaluating brincidofovir for the treatment of adenovirus infection in immunocompromised patients. Adenovirus is a common virus that leads to upper respiratory or gastrointestinal infections in individuals with a healthy immune system, but it can be rapidly fatal in individuals with a weakened immune system, particularly those who have recently undergone a hematopoietic cell transplant (HCT), or bone marrow transplant. There is no approved antiviral treatment for adenovirus infection.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|